Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug

Zhao, Kai; Li, Dan; Shi, Ci; Ma, Xueling; Rong, Guangu; Kang, Hong; Wang, Xiaohua; Sun, Bin

doi:10.2174/156720181304160521004609

Cited by 51 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this work, the MZ1-ACNPs obtained were characterized by size, PdI, and superficial charge ( Table 1 and Figure 1 ). The average ACNPs size was 114 nm, which is in the same range reported for other authors for drug encapsulation in polymeric nanoparticles [ 35 ]. Once MZ1-NPs formulation was optimized, reaching an EE value of 50%, trastuzumab conjugation was carried out following covalent binding by EDC/NHS chemistry.…”

Section: Discussionsupporting

confidence: 80%

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Bromo and extraterminal domain (BET) inhibitors-PROteolysis TArgeting Chimera (BETi-PROTAC) is a new family of compounds that induce proteasomal degradation through the ubiquitination of the tagged to BET inhibitors Bromodomain proteins, BRD2 and BRD. The encapsulation and controlled release of BET-PROTACs through their vectorization with antibodies, like trastuzumab, could facilitate their pharmacokinetic and efficacy profile. Antibody conjugated nanoparticles (ACNPs) using PROTACs have not been designed and evaluated. In this pioneer approach, the commercial MZ1 PROTAC was encapsulated into the FDA-approved polymeric nanoparticles. The nanoparticles were conjugated with trastuzumab to guide the delivery of MZ1 to breast tumoral cells that overexpress HER2. These ACNPs were characterized by means of size, polydispersity index, and Z-potential. Morphology of the nanoparticles, along with stability and release studies, completed the characterization. MZ1-loaded ACNPs showed a significant cytotoxic effect maintaining its mechanism of action and improving its therapeutic properties.

show abstract

Section: Discussionsupporting

confidence: 80%

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recently, several novel delivery strategies have been developed to reduce off-target effects, especially nanoparticles that are characteristic by improved stability, extremely small size, biocompatibility and selfassembly. 145,146 Administration of HOTAIR siRNA by using magnetic nanoparticles has been shown to effectively inhibit the proliferation, invasion and in vivo tumourigenicity of human glioma stem cells. 147 The use of nanoparticles as effective delivery vehicles for lncRNAs is thus highly attractive and deserves further studies.…”

Section: Discussionmentioning

confidence: 99%

“…A major challenge of all of these approaches is to accomplish target‐specific delivery. Recently, several novel delivery strategies have been developed to reduce off‐target effects, especially nanoparticles that are characteristic by improved stability, extremely small size, biocompatibility and self‐assembly . Administration of HOTAIR siRNA by using magnetic nanoparticles has been shown to effectively inhibit the proliferation, invasion and in vivo tumourigenicity of human glioma stem cells .…”

Section: Discussionmentioning

confidence: 99%

lncRNAs: novel players in intervertebral disc degeneration and osteoarthritis

et al. 2016

View full text Add to dashboard Cite

The term long non-coding RNA (lncRNA) refers to a group of RNAs with length more than 200 nucleotides, limited protein-coding potential, and having widespread biological functions, including regulation of transcriptional patterns and protein activity, formation of endogenous small interfering RNAs (siRNAs) and natural microRNA (miRNA) sponges. Intervertebral disc degeneration (IDD) and osteoarthritis (OA) are the most common chronic, prevalent and age-related degenerative musculoskeletal disorders. Numbers of lncRNAs are differentially expressed in human degenerative nucleus pulposus tissue and OA cartilage. Moreover, some lncRNAs have been shown to be involved in multiple pathological processes during OA, including extracellular matrix (ECM) degradation, inflammatory responses, apoptosis and angiogenesis. In this review, we summarize current knowledge concerning lncRNAs, from their biogenesis, classification and biological functions to molecular mechanisms and therapeutic potential in IDD and OA. are the most common chronic, prevalent and age-related degenerative musculoskeletal disorders, leading to an enormous socioeconomic burden worldwide. IDD and OA are two major causes of disability and chronic pain, and their incidence has been increasing not only among older persons but also within younger adults in the past decades. It is estimated that approximately 80% adults will suffer chronic low back pain caused by IDD during their lifetime.1 Over 50% of patients with symptomatic OA are younger than 65 years old.

show abstract

“…Polymeric nanoparticles provide significant stability, high drug loading ability, controlled drug release, and excellent biocompatibility, thus was widely applied as gene and drug delivery system. [18][19][20] In our previous study, colorectal cancer was treated with 5-Fluorouracil (5-FU) and enhanced GFP (EGFP) codelivered polymeric nanoparticles and achieved effective combination results. 21 Lipid nanoparticles/liposomes are biocompatible and can be used for the specific delivery of gene/drug to tumor tissues and also render them long circulatory lifetime.…”

Section: Introductionmentioning

confidence: 99%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy. Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model. Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (C max) and half-life (T 1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/ D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo. Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.

show abstract

Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug

Abstract: The findings of this review identified that the biodegradable polymeric nanoparticles were used as delivery carrier for drug currently. It also indicates that the biodegradable polymeric nanoparticles play an important role in the drug delivery.

Cited by 51 publications

References 0 publications

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

lncRNAs: novel players in intervertebral disc degeneration and osteoarthritis

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Contact Info

Product

Resources

About